choroidal neovascularization

• European Union
• Government
• Healthcare
• Pharma & Biotech
• Switzerland

The European Commission approved Novartis drug Lucentis as first effective anti-VEGF treatment for myopic choroidal neovascularization

Lucentis® (ranibizumab) is the first licensed therapy to improve vision in patients with visual impairment due to choroidal neovascularization secondary to…